Brain Wealthy
    What's Hot

    Global Accessibility Awareness Day: Building Accessibility into Technology | By Ed Lovelock | Starship Technologies | May 2023

    May 18, 2023

    Providing a greener future.On this Earth Day we encourage… | Redete Nardos | | Starship Technologies | April 2023

    April 21, 2023

    Starship Technologies Sets New World Record with 10 Million Kilometers | Reed Zula | | Starship Technologies | April 2023

    April 3, 2023
    Facebook Twitter Instagram
    Facebook Twitter Instagram
    Brain Wealthy
    • Home
    • Anxiety

      FSU psychologist receives $3.7 million grant to combat anxiety in seniors with Alzheimer’s and cognitive impairment

      February 2, 2023

      How anxiety came to dominate the big business of medical marijuana cards in Pa.

      February 2, 2023

      How to Reduce Anxiety in Stressful Situations

      February 2, 2023

      The cat in boots The last wish taught me about anxiety

      February 2, 2023

      Inseparable cat trio with ‘separation anxiety brothers’ find new home

      February 2, 2023
    • Emotion

      Leigh-Anne Pinnock shares emotional post about embarking on her solo career

      February 2, 2023

      Ontario paramedic emotional during last radio call

      February 2, 2023

      A Pianist Faces Death and Recorded Music of Unspeakable Emotions

      February 2, 2023

      Return of home post linking Gichaara to ancestors is emotional for north coast nation

      February 2, 2023

      Mother of two sues New York school district for ‘mental distress’ caused by mask enforcement

      February 2, 2023
    • Neurology

      Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

      February 2, 2023

      REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

      February 2, 2023

      Aducanumab for the treatment of Alzheimer’s disease

      February 2, 2023

      Potential for Effective Comparative Studies and Treatment Approval in Epilepsy Care: Anup Patel, MD

      February 2, 2023

      Head injury does not predict memory impairment in NFL retirees, UT Southwestern study shows: Newsroom

      February 2, 2023
    • Sleep

      Review: Never Sleep Again: The Elm Street Legacy – Blu-ray

      February 2, 2023

      Get a better night’s sleep with better pillows from The Pillow Bar in Dallas

      February 2, 2023

      Is it okay to sleep with a necklace on?

      February 2, 2023

      Does tart cherry juice improve sleep?

      February 2, 2023

      Social Jet Lag, Sleep Chronotypes, and Why We Gotta Close Our Eyes and Embrace It

      February 2, 2023
    • Brain Research

      spark!Talk – video available online

      February 2, 2023

      Studies have found that obesity-related neurodegeneration mimics Alzheimer’s disease.newsroom

      February 2, 2023

      The Brain Observatory: New Museum to Participate in Museum Month

      February 1, 2023

      who wants to live forever

      February 1, 2023

      UK company makes surprise forays

      February 1, 2023
    • Brain Wealth
      1. Mental Health
      2. View All

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023

      Research project applies a global lens to student mental health

      February 2, 2023

      DC Metro shooting suspect undergoes mental health evaluation after rampage

      February 2, 2023

      Gov. Ho-Chol unveils details of $1 billion plan to overhaul New York State’s mental health care continuum

      February 2, 2023

      Boston, we have a problem: data on mental health and practice come in

      February 2, 2023
    Brain Wealthy
    Home»Neurology»AffaMed Therapeutics Commercializes Galcanezumab for Migraine Prevention in Mainland China
    Neurology

    AffaMed Therapeutics Commercializes Galcanezumab for Migraine Prevention in Mainland China

    brainwealthy_vws1exBy brainwealthy_vws1exJanuary 17, 2023No Comments4 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    affirm get sole commercialization Rights Under Regulatory Approvals Mainland China to Galcanezumab, a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). It aims to address the unmet medical needs of millions of migraine sufferers in China.

    Shanghai, January 17, 2023 /PRNewswire/ — AffaMed Therapeutics (“AffaMed”) today announced that it is a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet medical needs in neurological, psychiatric and ocular diseases. and Eli Lilly and Company (“Eli Lilly”) intends to acquire the exclusive commercialization rights to import, market, promote, distribute and refine galcanezumab after approval in mainland China. increase. Lilly has submitted a new drug application for galcanezumab for the prophylaxis and treatment of episodic migraines in adults in the United States. Chinese National Medical Products Administration (“NMPA”) June 2022.

    Migraine is a disabling neurological disease that affects nearly 1 in 10 Chinese and an estimated 130 million patients, approximately two-thirds of whom are women.[1]Despite its high prevalence, migraine remains underrecognized and undertreated. ChinaBased on years of scientific and commercial experience and insights in the Chinese migraine market, AffaMed has established this partnership with Eli Lilly to address a critical unmet need and improve quality of life for migraine sufferers. view it as an important opportunity to improve. China.

    “We are thrilled to have reached an agreement with Eli Lilly to bring this innovative product to Chinese patients suffering from migraine headaches, a condition that dramatically impairs their quality of life.” Zhao TaoyoAffaMed’s CEO commented:

    In Phase 3 PERSIST[2]A study, randomized, double-blind, placebo-controlled pivotal trial was designed to evaluate the efficacy and safety of galcanezumab in patients with episodic migraine from . China, IndiaWhen Russia, the least-squares (LS) mean reduction from baseline in monthly MHD over 3 months was significantly greater with galcanezumab compared with placebo (-3.81 days vs. -1.99 days; p < 0.0001). A significantly higher mean proportion of patients in the galcanezumab and placebo groups decreased MHD from baseline by ≥50%, ≥75% and 100% (all p < 0.0001).

    About migraines

    Migraine is a severe, disabling neurological disorder characterized by recurrent episodes of moderate to severe headache accompanied by other symptoms such as nausea, sensitivity to light and sensitivity to sound.[3],[4] The prevalence in Chinese is 9.3%, while the prevalence in women is 12.8%, more than double the prevalence in men of 5.8%.[1] It is reported to be the second most disabling disease affecting daily life of all diseases.[5]

    About galcanezumab

    Galcanezumab is a monoclonal antibody that selectively binds to calcitonin gene-related peptide (CGRP). Developed by Eli Lilly and approved by the FDA. September 2018 Prophylactic treatment of migraine in adults, and June 2019 For the treatment of episodic cluster headaches in adults. Galcanezumab (under the brand name Emgality® usa) is an innovative therapeutic approach to this neurological disorder and is also the first and only drug approved by the US FDA to reduce the number of attacks for the treatment of episodic cluster headache. It is currently used by migraine sufferers in 20 countries around the world.

    About AffaMed Therapeutics

    AffaMed Therapeutics is a clinical-stage biopharmaceutical company with innovative pharmaceutical, digital and surgical products that address significant unmet medical needs in ophthalmic, neurological and psychiatric disorders in ophthalmic, neurological and psychiatric patients focused on the development and commercialization of Greater China and around the world. AffaMed Therapeutics’ management team has acquired deep industry expertise and extensive experience in high-quality discovery, clinical development, regulatory affairs, business development, manufacturing, and commercial operations with leading multinational biopharmaceutical companies. I’m here. China and globally.

    Disclaimer

    The product mentioned is currently an investigational drug for the indicated indication and is not yet approved in mainland China. Affamed and Lilly do not endorse the use of unapproved medicines or indications.

    References

    [1]Yu S, Liu R, Zhao G, et al. Prevalence and Burden of Primary Headache in China: A Population-Based Visitor Survey. headache. 2012, 52:582-591.

    [2]Hu et al. Phase 3, Randomized, Double-Blind, Placebo-Controlled PERSIST Study, The Journal of Headache and Pain. 2022

    [3]Katsarava Z, Buse D, Manack A, et al. Definition of the difference between episodic and chronic migraine. Current pain headache report. 2012; 16:86.

    [4]Blumenfeld AM, Payne KA, Varon SF, et al. Disability, HRQOL, and resource use in patients with chronic and episodic migraine. Results from the International Burden of Migraine Study (IBMS). headache. 2011;31:301.

    [5]GBD 2016 Headache Collaborators (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis of the 2016 Global Burden of Disease Study. Lancet Neurol 17(11):954. –76

    Source AffaMed Therapeutics Ltd.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleObserving the Sabers: Panthers loss premature emotional disappointment for Buffalo
    Next Article IBRO/IBE-UNESCO Science of Learning Fellowships 2023 (up to €20,000)
    brainwealthy_vws1ex
    • Website

    Related Posts

    Gardasil Injection Lawsuit Claims HPV Vaccine Caused Neurological and Autonomic Dysfunction

    February 2, 2023

    REGENXBIO’s Duchenne Therapy RGX-202 Clinical Trial Begins Patient Recruitment

    February 2, 2023

    Aducanumab for the treatment of Alzheimer’s disease

    February 2, 2023
    Add A Comment

    Leave A Reply Cancel Reply

    Top Posts

    Subscribe to Updates

    Get the latest sports news from SportsSite about soccer, football and tennis.

    This website provides information about Brain and other things. Keep Supporting Us With the Latest News and we Will Provide the Best Of Our To Makes You Updated All Around The World News. Keep Sporting US.

    Facebook Twitter Instagram Pinterest YouTube
    Top Insights

    Top UK Stocks to Watch: Capita Shares Rise as it Unveils

    January 15, 2021
    8.5

    Digital Euro Might Suck Away 8% of Banks’ Deposits

    January 12, 2021

    Oil Gains on OPEC Outlook That U.S. Growth Will Slow

    January 11, 2021
    Get Informed

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2023 brainwealthy. Designed by brainwealthy.
    • Home
    • Contact us
    • DMCA
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.